Literature DB >> 17407163

RNASEL Arg462Gln polymorphism and prostate cancer in PLCO.

Sarah E Daugherty1, Richard B Hayes, Meredith Yeager, Gerald L Andriole, Nilanjan Chatterjee, Wen-Yi Huang, William B Isaacs, Elizabeth A Platz.   

Abstract

BACKGROUND: The Gln allele of the Arg462Gln polymorphism in RNASEL results in a threefold decrease in enzymatic activity, a reported deficiency in apoptotic response, and has been associated with prostate cancer in some high-risk family studies. The relationship of this variant to sporadic prostate cancer remains uncertain.
METHODS: We conducted a nested case-control study of 1,317 prostate cancer cases and 1,842 controls from the screening arm of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Conditional logistic regression was used to evaluate the association between the RNASEL Arg462Gln polymorphism and prostate cancer.
RESULTS: No statistically significant association was observed between the Arg462Gln polymorphism and prostate cancer (compared to Arg/Arg, Gln/Arg: OR= 0.99 95% CI 0.84-1.16; Gln/Gln: OR= 0.95 95% CI 0.74-1.21), although slight non-significant differences in risk were observed among men with the Gln/Gln genotype by stage and grade.
CONCLUSIONS: These results suggest that the RNASEL Gln/Gln genotype does not play an important role in the etiology of prostate cancer in the general population. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17407163     DOI: 10.1002/pros.20537

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  17 in total

1.  An update analysis of two polymorphisms in encoding ribonuclease L gene and prostate cancer risk: involving 13,372 cases and 11,953 controls.

Authors:  Yuan-Yuan Mi; Li-Jie Zhu; Sheng Wu; Ning-Han Feng
Journal:  Genes Nutr       Date:  2011-04-17       Impact factor: 5.523

2.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer.

Authors:  David J Hunter; Peter Kraft; Kevin B Jacobs; David G Cox; Meredith Yeager; Susan E Hankinson; Sholom Wacholder; Zhaoming Wang; Robert Welch; Amy Hutchinson; Junwen Wang; Kai Yu; Nilanjan Chatterjee; Nick Orr; Walter C Willett; Graham A Colditz; Regina G Ziegler; Christine D Berg; Saundra S Buys; Catherine A McCarty; Heather Spencer Feigelson; Eugenia E Calle; Michael J Thun; Richard B Hayes; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert N Hoover; Gilles Thomas; Stephen J Chanock
Journal:  Nat Genet       Date:  2007-05-27       Impact factor: 38.330

3.  RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: evidences from a meta-analysis.

Authors:  Bingbing Wei; Zhuoqun Xu; Jun Ruan; Ming Zhu; Ke Jin; Deqi Zhou; Zhiqiang Yan; Feng Xuan; Hongyi Zhou; Xing Huang; Jian Zhang; Peng Lu; Jianfeng Shao
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

4.  Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Authors:  Danyelle A Winchester; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Regina M Santella; Teresa L Johnson-Pais; Robin J Leach; Jianfeng Xu; S Lilly Zheng; Ian M Thompson; M Scott Lucia; Scott M Lippman; Howard L Parnes; William B Isaacs; Angelo M De Marzo; Charles G Drake; Elizabeth A Platz
Journal:  Prostate       Date:  2017-03-20       Impact factor: 4.104

5.  Genetic variation in RNASEL associated with prostate cancer risk and progression.

Authors:  Mara S Meyer; Kathryn L Penney; Jennifer R Stark; Fredrick R Schumacher; Howard D Sesso; Massimo Loda; Michelangelo Fiorentino; Stephen Finn; Richard J Flavin; Tobias Kurth; Alkes L Price; Edward L Giovannucci; Katja Fall; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Carcinogenesis       Date:  2010-06-24       Impact factor: 4.944

6.  RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies.

Authors:  Li-Feng Zhang; Yuan-Yuan Mi; Chao Qin; Yong Wang; Qiang Cao; Jun-Feng Wei; Yao-Jun Zhou; Ning-Han Feng; Wei Zhang
Journal:  Mol Biol Rep       Date:  2011-01-09       Impact factor: 2.316

7.  A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.

Authors:  Jonathan D Schoenfeld; Danielle N Margalit; Julie L Kasperzyk; Irene M Shui; Jennifer R Rider; Mara M Epstein; Allison Meisner; Stacey A Kenfield; Neil E Martin; Paul L Nguyen; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; Lorelei A Mucci
Journal:  Clin Cancer Res       Date:  2013-02-04       Impact factor: 12.531

8.  Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.

Authors:  Christiane M Robbins; Wenndy Hernandez; Chiledum Ahaghotu; James Bennett; Gerald Hoke; Terry Mason; Curtis A Pettaway; Srinivasan Vijayakumar; Sally Weinrich; Paulette Furbert-Harris; Georgia Dunston; Isaac J Powell; John D Carpten; Rick A Kittles
Journal:  Prostate       Date:  2008-12-01       Impact factor: 4.104

9.  Sexually transmissible infections and prostate cancer risk.

Authors:  Wen-Yi Huang; Richard Hayes; Ruth Pfeiffer; Raphael P Viscidi; Francis K Lee; Yun F Wang; Douglas Reding; Denise Whitby; John R Papp; Charles S Rabkin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

10.  Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.

Authors:  Ming-Hsi Wang; Kathy J Helzlsouer; Michael W Smith; Judith A Hoffman-Bolton; Sandra L Clipp; Viktoriya Grinberg; Angelo M De Marzo; William B Isaacs; Charles G Drake; Yin Yao Shugart; Elizabeth A Platz
Journal:  Prostate       Date:  2009-06-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.